169 related articles for article (PubMed ID: 25077773)
1. Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.
Okal A; Matissek KJ; Matissek SJ; Price R; Salama ME; Janát-Amsbury MM; Lim CS
Gene Ther; 2014 Oct; 21(10):903-12. PubMed ID: 25077773
[TBL] [Abstract][Full Text] [Related]
2. A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.
Okal A; Mossalam M; Matissek KJ; Dixon AS; Moos PJ; Lim CS
Mol Pharm; 2013 Oct; 10(10):3922-33. PubMed ID: 23964676
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated p53 and ING4 gene co-transfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer.
Wu J; Zhu Y; Xu C; Xu H; Zhou X; Yang J; Xie Y; Tao M
Oncol Rep; 2016 Jan; 35(1):243-52. PubMed ID: 26530780
[TBL] [Abstract][Full Text] [Related]
4. Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.
Okal A; Cornillie S; Matissek SJ; Matissek KJ; Cheatham TE; Lim CS
Mol Pharm; 2014 Jul; 11(7):2442-52. PubMed ID: 24836513
[TBL] [Abstract][Full Text] [Related]
5. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
6. Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth.
Alam S; Bowser BS; Israr M; Conway MJ; Meyers C
Cancer Biol Ther; 2014 Aug; 15(8):1013-28. PubMed ID: 24834917
[TBL] [Abstract][Full Text] [Related]
7. Tumor-suppressive effect of adenovirus-mediated inhibitor of growth 4 gene transfer in breast carcinoma cells in vitro and in vivo.
Li Z; Xie Y; Sheng W; Miao J; Xiang J; Yang J
Cancer Biother Radiopharm; 2010 Aug; 25(4):427-37. PubMed ID: 20707719
[TBL] [Abstract][Full Text] [Related]
8. CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression.
Ning Y; Wang C; Liu X; Du Y; Liu S; Liu K; Zhou J; Zhou C
J Exp Clin Cancer Res; 2019 Mar; 38(1):131. PubMed ID: 30885251
[TBL] [Abstract][Full Text] [Related]
9. p53-Bad: A Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the Mitochondria for Ovarian Cancer Gene Therapy.
Lu P; Redd Bowman KE; Brown SM; Joklik-Mcleod M; Vander Mause ER; Nguyen HTN; Lim CS
Mol Pharm; 2019 Aug; 16(8):3386-3398. PubMed ID: 31241338
[TBL] [Abstract][Full Text] [Related]
10. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer.
Zhang YF; Zhang BC; Zhang AR; Wu TT; Liu J; Yu LF; Wang WX; Gao JF; Fang DC; Rao ZG
Oncol Rep; 2013 Oct; 30(4):1989-95. PubMed ID: 23933826
[TBL] [Abstract][Full Text] [Related]
11. Recombinant GnRH-p53 protein sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis in vitro and in vivo.
Lu Y; Zhang Z; Yan Z; Chen L; Deng W; Lotze M; Wang Z; Lin X; Li LY
Apoptosis; 2013 Oct; 18(10):1214-23. PubMed ID: 23801079
[TBL] [Abstract][Full Text] [Related]
12. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants.
Waterman MJ; Waterman JL; Halazonetis TD
Cancer Res; 1996 Jan; 56(1):158-63. PubMed ID: 8548757
[TBL] [Abstract][Full Text] [Related]
13. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity.
Xu M; Kumar D; Srinivas S; Detolla LJ; Yu SF; Stass SA; Mixson AJ
Hum Gene Ther; 1997 Jan; 8(2):177-85. PubMed ID: 9017421
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.
Ito H; Kanzawa T; Miyoshi T; Hirohata S; Kyo S; Iwamaru A; Aoki H; Kondo Y; Kondo S
Hum Gene Ther; 2005 Jun; 16(6):685-98. PubMed ID: 15960600
[TBL] [Abstract][Full Text] [Related]
15. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
Lin F; Xie YJ; Zhang XK; Huang TJ; Xu HF; Mei Y; Liang H; Hu H; Lin ST; Luo FF; Lang YH; Peng LX; Qian CN; Huang BJ
J Exp Clin Cancer Res; 2019 Apr; 38(1):152. PubMed ID: 30961661
[TBL] [Abstract][Full Text] [Related]
16. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.
Liu W; Ip MM; Podgorsak MB; Das GM
Breast Cancer Res Treat; 2009 May; 115(1):43-50. PubMed ID: 18481172
[TBL] [Abstract][Full Text] [Related]
17. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.
D'Assoro AB; Leontovich A; Amato A; Ayers-Ringler JR; Quatraro C; Hafner K; Jenkins RB; Libra M; Ingle J; Stivala F; Galanis E; Salisbury JL
Int J Oncol; 2010 Nov; 37(5):1167-76. PubMed ID: 20878064
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF-κB and p53.
Zhang Y; Wu J; Jing H; Huang G; Sun Z; Xu S
J Cell Biochem; 2019 Apr; 120(4):6789-6797. PubMed ID: 30556250
[TBL] [Abstract][Full Text] [Related]
19. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
20. Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression.
Gogna R; Madan E; Kuppusamy P; Pati U
J Biol Chem; 2012 Jan; 287(4):2907-14. PubMed ID: 22147694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
